NUTRESTORE (l-glutamine) by Emmaus Life Sciences is l-glutamine in treating sickle cell disease (scd) is not fully understood. First approved in 2004.
Drug data last refreshed 3m ago · AI intelligence enriched 1w ago
NUTRESTORE is an oral L-glutamine solution approved for sickle cell disease (SCD) that works by improving NAD redox potential in sickle red blood cells through increased availability of reduced glutathione, thereby reducing oxidative stress and hemolysis. The mechanism addresses the fundamental pathophysiology of SCD by protecting sickle RBCs from oxidative damage that contributes to chronic hemolysis and vaso-occlusive events.
Product is approaching loss of exclusivity with minimal competitive pressure (30), suggesting commercial teams should prioritize market defense and lifecycle management initiatives.
L-glutamine in treating sickle cell disease (SCD) is not fully understood. Oxidative stress phenomena are involved in the pathophysiology of SCD. Sickle red blood cells (RBCs) are more susceptible to oxidative damage than normal RBCs, which may contribute to the chronic hemolysis and vaso-occlusive…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions
Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition
L-Glutamine Therapy for Sickle Cell Anemia
Worked on NUTRESTORE at Emmaus Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on NUTRESTORE offers opportunity to develop expertise in rare disease commercialization and lifecycle management in a stable but maturing orphan indication. Career trajectory is best suited for professionals interested in market defense, patient advocacy alignment, and navigating the transition to generic competition rather than high-growth expansion.